Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study

Published:2016-05 Issue:5 Volume:17 Page:600-611
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bertucci François,Fekih Mahmoud,Autret Aurélie,Petit Thierry,Dalenc Florence,Levy Christelle,Romieu Gilles,Bonneterre Jacques,Ferrero Jean-Marc,Kerbrat Pierre,Soulie Patrick,Mouret-Reynier Marie-Ange,Bachelot Thomas,Lerebours Florence,Eymard Jean-Christophe,Deblock Mathilde,Lortholary Alain,Hardy-Bessard Anne-Claire,Barthelemy Philippe,Bonnefoi Hervé,Charafe-Jauffret Emmanuelle,Bidard François-Clément,Viens Patrice,Lemonnier Jérôme,Pierga Jean-Yves

Publisher

Elsevier BV

Subject

Oncology

Reference51 articles.

1. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment;Dawood;Ann Oncol,2011

2. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma;Cristofanilli;Cancer,2001

3. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer;Adkins;J Clin Oncol,1999

4. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment;Bertucci;Bone Marrow Transplant,2004

5. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer;Cagnoni;J Clin Oncol,1998

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer;Cancer Research;2024-03-20

2. Personalized Medicine in Clinical Management of Breast Cancer: Where Do We Stand?;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

3. Advances in targets in inflammatory breast cancer;International Review of Cell and Molecular Biology;2024

4. Tailoring Treatment for Patients with Inflammatory Breast Cancer;Current Treatment Options in Oncology;2023-04-12

5. Radiation therapy and antiangiogenic therapy: Opportunities and challenges;Cancer/Radiothérapie;2022-10